The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | PET radiomic features associated with better outcomes after CAR-T therapy in patients with DLBCL
Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain, describes the findings of a study that aimed to establish radiomic signatures associated with a better response to CAR-T therapy in patients with diffuse large B-cell lymphoma (DLBCL). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Allogene, Amgen, BMS, Gilead, Incyte, Jazz Pharmaceuticals, Miltenyi Biomedicine, Nektar and Novartis: Consultancy.
